Morningstar brands and products Company Portfolio ...

YAQ006 and YAQ007 are, respectively, the intravenous and oral formulations of L-ornithine phenylacetate (L-OPA), a potent ammonia-scavenging agent. Yaqrit is preparing to start a phase 3 trial ...

A decrease in VLCFA levels in brain, the main tissue affected in X-ALD, is likely because it has been shown that phenylacetate, the initial product of 4PBA breakdown, can cross the blood–brain ...